neo212
Generic: Temozolomide Perillyl Alcohol Conjugate NEO212·Code: NEO212
neo212: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | Phase 1/Phase 2 |
Clinical Trials (1)
An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.
Frequently asked questions
Who is developing neo212?
neo212 is being developed by NEONC TECHNOLOGIES HOLDINGS, INC..
How many clinical trials involve neo212?
BioSniper tracks 1 clinical trial involving neo212.
Get deeper analysis on neo212
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis